Cargando…

Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus

Vaccines against dengue virus (DV) are commercially nonexistent. A subunit vaccination strategy may be of value, especially if a safe viral vector acts as biologically active adjuvant. In this paper, we focus on an immunoglobulin-like, independently folded domain III (DIII) from DV 2 envelope protei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harahap-Carrillo, Indira S., Ceballos-Olvera, Ivonne, Reyes-del Valle, Jorge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586464/ https://www.ncbi.nlm.nih.gov/pubmed/26350592 http://dx.doi.org/10.3390/vaccines3030503

Ejemplares similares

Dengue-specific subviral nanoparticles: design, creation and characterization
por: Khetarpal, Niyati, et al.
Publicado: (2013)

Dengue virus type-3 envelope protein domain III; expression and immunogenicity
por: Fahimi, Hossein, et al.
Publicado: (2014)

Subviral Agents
por: STRAUSS, JAMES H., et al.
Publicado: (2008)

Immunogenicity of a novel tetravalent dengue envelope protein domain III-based antigen in mice
por: Fahimi, Hossein, et al.
Publicado: (2018)

Production of dengue 2 envelope domain III in plant using CPMV - based vector system
por: Carlos Marques, Lívia Érika, et al.
Publicado: (2014)

Incorporation of apolipoprotein E into HBV–HCV subviral envelope particles to improve the hepatitis vaccine strategy
por: Gomez-Escobar, Elsa, et al.
Publicado: (2021)

Diagnostic Performance of Dengue Virus Envelope Domain III in Acute Dengue Infection
por: Nguyen, Ngoc Minh, et al.
Publicado: (2019)

Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice
por: Chiang, Chen-Yi, et al.
Publicado: (2016)

Subviral particle as vaccine and vaccine platform
por: Tan, Ming, et al.
Publicado: (2014)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
por: López-Camacho, César, et al.
Publicado: (2020)

Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2
por: Arora, Upasana, et al.
Publicado: (2012)

Recognition of heparan sulfate by clinical strains of dengue virus serotype 1 using recombinant subviral particles
por: Artpradit, Charlermchai, et al.
Publicado: (2013)

Phage Display Approaches for the Isolation of Monoclonal Antibodies Against Dengue Virus Envelope Domain III from Human and Mouse Derived Libraries
por: Moreland, Nicole J., et al.
Publicado: (2012)

Display of the HIV envelope protein at the yeast cell surface for immunogen development
por: Mathew, Elizabeth, et al.
Publicado: (2018)

Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III
por: Matsui, Kiyohiko, et al.
Publicado: (2010)

A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies
por: Chua, Anthony JS, et al.
Publicado: (2013)

Molecular Changes in Dengue Envelope Protein Domain III upon Interaction with Glycosaminoglycans
por: Hyatt, James G., et al.
Publicado: (2020)

Efficient Assembly and Secretion of Recombinant Subviral Particles of the Four Dengue Serotypes Using Native prM and E Proteins
por: Wang, Pei-Gang, et al.
Publicado: (2009)

Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates
por: Rossi, Shannan L, et al.
Publicado: (2019)

Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine
por: Wang, Xinyi, et al.
Publicado: (2019)

Immunological Analysis of Nodavirus Capsid Displaying the Domain III of Japanese Encephalitis Virus Envelope Protein
por: Kumar, Kiven, et al.
Publicado: (2021)

Development of flavivirus subviral particles with low cross-reactivity by mutations of a distinct antigenic domain
por: Tabata, Koshiro, et al.
Publicado: (2023)

Addition of Partial Envelope Domain II into Envelope Domain III of Dengue Virus Antigen Potentiates the Induction of Virus-Neutralizing Antibodies and Induces Protective Immunity
por: Park, Jisang, et al.
Publicado: (2020)

The Fittest versus the Flattest: Experimental Confirmation of the Quasispecies Effect with Subviral Pathogens
por: Codoñer, Francisco M, et al.
Publicado: (2006)

An Attenuated Strain of Human Cytomegalovirus for the Establishment of a Subviral Particle Vaccine
por: Krauter, Steffi, et al.
Publicado: (2022)

In silico binding analysis of lutein and rosmarinic acid against envelope domain III protein of dengue virus
por: Panchal, Ritesh, et al.
Publicado: (2021)

Use of a commercial enzyme immunoassay to monitor dengue virus replication in cultured cells
por: Ludert, Juan E, et al.
Publicado: (2008)

Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms
por: Ho, Joan Kha-Tu, et al.
Publicado: (2020)

DNA Vaccines against Dengue Virus Type 2 Based on Truncate Envelope Protein or Its Domain III
por: Azevedo, Adriana S., et al.
Publicado: (2011)

Casamino acids facilitate the secretion of recombinant dengue virus serotype-3 envelope domain III in Pichia pastoris
por: Kaushik, Neha, et al.
Publicado: (2016)

In silico analysis of an envelope domain III-based multivalent fusion protein as a potential dengue vaccine candidate
por: Fahimi, Hossein, et al.
Publicado: (2016)

Characterization of a Novel Dengue Serotype 4 Virus-Specific Neutralizing Epitope on the Envelope Protein Domain III
por: Ji, Guang-Hui, et al.
Publicado: (2015)

A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III
por: Hu, Dan, et al.
Publicado: (2019)

Expression of an immunocomplex consisting of Fc fragment fused with a consensus dengue envelope domain III in Saccharomyces cerevisiae
por: So, Kum-Kang, et al.
Publicado: (2021)

Subviral Dense Bodies of Human Cytomegalovirus Induce an Antiviral Type I Interferon Response
por: Penner, Inessa, et al.
Publicado: (2022)

Dengue-1 Envelope Protein Domain III along with PELC and CpG Oligodeoxynucleotides Synergistically Enhances Immune Responses
por: Chiang, Chen-Yi, et al.
Publicado: (2012)

Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA Vaccine Comprising Envelope Domain III in Mice
por: Kulkarni, Ajit, et al.
Publicado: (2017)

Dengue Virus Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent NETosis-Mediated Inflammation in Mice
por: Lien, Te-Sheng, et al.
Publicado: (2021)

Exposure to Dengue Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent Endothelial Dysfunction and Hemorrhage in Mice
por: Lien, Te-Sheng, et al.
Publicado: (2021)

Natural immunogenic properties of bioinformatically predicted linear B-cell epitopes of dengue envelope and pre-membrane proteins
por: Nadugala, Mahesha N., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a4mufdpml0jnj2kduon75fl1gt